End-to-end deep learning radiomics: development and validation of a novel attention-based aggregate convolutional neural network to distinguish breast diffuse large B-cell lymphoma from breast invasive ductal carcinoma.

BACKGROUND: Apart from invasive pathological examination, there is no effective method to differentiate breast diffuse large B-cell lymphoma (DLBCL) from breast invasive ductal carcinoma (IDC). In this study, we aimed to develop and validate an effective deep learning radiomics model to discriminate between DLBCL and IDC.

METHODS: A total of 324 breast nodules from 236 patients with baseline 18 F-fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography (PET/CT) were retrospectively analyzed. After grouping breast DLBCL and breast IDC patients, external and internal datasets were divided according to the data collected by different centers. Preprocessing was then used to process the original PET/CT images and an attention-based aggregate convolutional neural network (AACNN) model was designed. The AACNN model was trained using patches of CT or PET tumor images and optimized with an improved loss function. The final ensemble predictive model was built using distance weight voting. Finally, the model performance was evaluated and statistically verified.

RESULTS: A total of 249 breast nodules from Fudan University Shanghai Cancer Center (FUSCC) and 75 breast nodules from Shanghai Proton and Heavy Ion Center (SPHIC) were selected as internal and external datasets, respectively. On the internal testing, our method yielded an area under the curve (AUC), accuracy (ACC), sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV), and harmonic mean of precision and sensitivity (F1) of 0.886, 83.0%, 80.9%, 85.0%, 84.8%, 81.2%, and 0.828, respectively. Meanwhile on the external testing, the results were 0.788, 71.6%, 61.4%, 84.7%, 84.0%, 62.6%, and 0.709, respectively.

CONCLUSIONS: Our study outlines a deep learning radiomics method which can automatically, noninvasively, and accurately differentiate breast DLBCL from breast IDC, which will be more in line with the needs and strategies of precision medicine, individualized diagnosis, and treatment.